NCT04756206 - Role of Dutasteride in Treatment of Chronic Prostatitis | Biotech Hunter

Enrollment

50

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

September 1, 2020

Conditions

DutasterideCategory IIIB Chronic Prostatitis

Interventions

DRUG

Dutasteride 0.5 mg

patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.

DRUG

Placebo

patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.

Trial Locations (1)

11361

Urology department - ain shams university, Cairo